Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

MALVERN, Pa., April 02, 2024 -- Annovis Bio, Inc. , a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates...

Related Keywords

United States ,Malvern ,Pennsylvania ,Annovis Bio ,Maria Maccecchini ,Andrew Walsh ,Marial Maccecchini ,Securities Exchange ,Pq Corporation ,Annovis Bio Inc ,Company Annual Report On Form ,European Union ,Twitter ,Your Strategic Mission ,Inventiv Health ,Linkedin ,Potters Industries ,Last Patient Visit ,Full Enrollment ,Trial Exceeding Original ,Novel Biomarker Measurements ,Vice President ,Senior Director ,Strategic Mission ,Current Leadership ,Fourth Quarter ,Full Year ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,